News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2018

24 December, 2018 PledPharma applies for an Orphan Drug Designation (ODD) in the US for Aladote News English Regulatory IR Optional
5 December, 2018 PledPharma prepares for listing on the Nasdaq Stockholm main market during 2019 News English Regulatory IR Optional
8 November, 2018 The first patient included in PledPharma’s global Phase III program for PledOx® News English Regulatory IR Optional
26 October, 2018 Nomination Committee appointed for the 2019 Annual General Meeting in PledPharma News English Regulatory IR Optional
23 October, 2018 Interim Report January-September 2018 News English Regulatory MAR Report Interim Q3 IR Optional
28 September, 2018 Study drug for the PledOx® global phase III program delivered News English Regulatory IR Optional
24 September, 2018 Pledpharma announces positive results from the Aladote® proof of principle study News English Regulatory IR Optional
22 August, 2018 Half-Year Report January-June 2018 News English Regulatory MAR Report Interim Q2 IR Optional
15 August, 2018 Delivery of study drug to the PledOx® phase III program is expected in September News English Regulatory IR Optional
24 April, 2018 Interim Report January-March 2018 News English Regulatory MAR Report Interim Q1 IR Optional

Calendar and upcoming reports

May 3, 2024
Interim Report Q1 2024 (7:00am CEST)

May 6, 2024
Annual General Meeting

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com